CR20220072A - Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias - Google Patents
Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratoriasInfo
- Publication number
- CR20220072A CR20220072A CR20220072A CR20220072A CR20220072A CR 20220072 A CR20220072 A CR 20220072A CR 20220072 A CR20220072 A CR 20220072A CR 20220072 A CR20220072 A CR 20220072A CR 20220072 A CR20220072 A CR 20220072A
- Authority
- CR
- Costa Rica
- Prior art keywords
- tmem16a
- modulators
- treatment
- pyridine derivatives
- respiratory disorders
- Prior art date
Links
- 102000003787 Anoctamin-1 Human genes 0.000 title 1
- 108090000160 Anoctamin-1 Proteins 0.000 title 1
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
- 208000023504 respiratory system disease Diseases 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1910607.9A GB201910607D0 (en) | 2019-07-24 | 2019-07-24 | Compounds |
| GBGB2005739.4A GB202005739D0 (en) | 2020-04-20 | 2020-04-20 | Compounds |
| PCT/GB2020/051778 WO2021014166A1 (en) | 2019-07-24 | 2020-07-24 | Pyridine derivatives as tmem16a modulators for use in the treatment of respiratory conditions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20220072A true CR20220072A (es) | 2022-06-29 |
Family
ID=71948615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20220072A CR20220072A (es) | 2019-07-24 | 2020-07-24 | Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20220235006A1 (enExample) |
| EP (1) | EP4003516A1 (enExample) |
| JP (1) | JP7583022B2 (enExample) |
| KR (1) | KR20220063162A (enExample) |
| CN (1) | CN114616226B (enExample) |
| AU (1) | AU2020317036A1 (enExample) |
| BR (1) | BR112022001164A2 (enExample) |
| CA (1) | CA3145120A1 (enExample) |
| CL (1) | CL2022000147A1 (enExample) |
| CO (1) | CO2022002022A2 (enExample) |
| CR (1) | CR20220072A (enExample) |
| IL (1) | IL290035A (enExample) |
| MX (1) | MX2022000841A (enExample) |
| PE (1) | PE20221441A1 (enExample) |
| PH (1) | PH12022550181A1 (enExample) |
| WO (1) | WO2021014166A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20221441A1 (es) * | 2019-07-24 | 2022-09-21 | Tmem16A Ltd | Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias |
| KR20260025059A (ko) * | 2024-08-13 | 2026-02-23 | 전남대학교산학협력단 | 신규한 치환된 피리딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050176767A1 (en) * | 2003-10-30 | 2005-08-11 | Laval Chan Chun Kong | Pyridine carboxamide and methods for inhibiting HIV integrase |
| EP3612180B1 (en) * | 2017-04-17 | 2023-10-11 | The Regents of the University of California | Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel tmem16a |
| GB201801355D0 (en) * | 2018-01-26 | 2018-03-14 | Enterprise Therapeutics Ltd | Compounds |
| PE20221441A1 (es) * | 2019-07-24 | 2022-09-21 | Tmem16A Ltd | Derivados de piridina como moduladores de tmem16a para su uso en el tratamiento de afecciones respiratorias |
-
2020
- 2020-07-24 PE PE2022000119A patent/PE20221441A1/es unknown
- 2020-07-24 EP EP20751234.4A patent/EP4003516A1/en active Pending
- 2020-07-24 KR KR1020227006371A patent/KR20220063162A/ko not_active Ceased
- 2020-07-24 BR BR112022001164A patent/BR112022001164A2/pt not_active Application Discontinuation
- 2020-07-24 CN CN202080053192.6A patent/CN114616226B/zh active Active
- 2020-07-24 PH PH1/2022/550181A patent/PH12022550181A1/en unknown
- 2020-07-24 CR CR20220072A patent/CR20220072A/es unknown
- 2020-07-24 WO PCT/GB2020/051778 patent/WO2021014166A1/en not_active Ceased
- 2020-07-24 AU AU2020317036A patent/AU2020317036A1/en not_active Abandoned
- 2020-07-24 JP JP2022504089A patent/JP7583022B2/ja active Active
- 2020-07-24 CA CA3145120A patent/CA3145120A1/en active Pending
- 2020-07-24 MX MX2022000841A patent/MX2022000841A/es unknown
-
2022
- 2022-01-21 US US17/581,504 patent/US20220235006A1/en active Pending
- 2022-01-21 CL CL2022000147A patent/CL2022000147A1/es unknown
- 2022-01-23 IL IL290035A patent/IL290035A/en unknown
- 2022-02-24 CO CONC2022/0002022A patent/CO2022002022A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2022000841A (es) | 2022-06-08 |
| WO2021014166A1 (en) | 2021-01-28 |
| CL2022000147A1 (es) | 2022-10-07 |
| PE20221441A1 (es) | 2022-09-21 |
| JP2022541311A (ja) | 2022-09-22 |
| PH12022550181A1 (en) | 2023-01-16 |
| KR20220063162A (ko) | 2022-05-17 |
| IL290035A (en) | 2022-03-01 |
| CO2022002022A2 (es) | 2022-06-10 |
| CA3145120A1 (en) | 2021-01-28 |
| US20220235006A1 (en) | 2022-07-28 |
| AU2020317036A1 (en) | 2022-03-17 |
| JP7583022B2 (ja) | 2024-11-13 |
| CN114616226A (zh) | 2022-06-10 |
| CN114616226B (zh) | 2025-03-04 |
| EP4003516A1 (en) | 2022-06-01 |
| BR112022001164A2 (pt) | 2022-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DOP2023000016A (es) | Macrociclos como moduladores del regulador de conductancia transmembrana de la fibrosis quística, composiciones farmacéuticas de estos, su uso en el tratamiento de la fibrosis quística y procesos para elaborarlos | |
| CY1124918T1 (el) | Ρυθμιστες ccr2 | |
| CY1125025T1 (el) | 2-φορμυλ-3-υδροξυφαινυλοξυμεθυλ ενωσεις ικανες ρυθμισης αιμοσφαιρινης | |
| EP4272731A3 (en) | Compositions for the delivery of therapeutic agents and methods of use and making thereof | |
| BR112017013661A8 (pt) | Conjugado derivado de antraciclina (pnu), conjugado de fármaco-proteína de ligação (bpdc), método para a produção de um conjugado de fármaco-proteína de ligação (bpdc), uso de um conjugado de proteína de ligação-fármaco (bpdc) e composição farmacêutica | |
| MX2024004531A (es) | Compuestos de piridazinona y usos de los mismos. | |
| MX2017007489A (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. | |
| ECSP17074645A (es) | Azabenzimidazoles y su uso como moduladores del receptor ampa | |
| BR112015023589A2 (pt) | método para a produção de um conjugado de imunoligante/carga útil, conjugado, uso de um conjugado, carga útil de baixo peso molecular e uso de uma carga útil | |
| CL2021001027A1 (es) | Inhibidores selectivos de rgmc y el uso de los mismos | |
| ECSP18049762A (es) | Nuevos anticuerpos anti-claudina y sus métodos de uso | |
| UY34350A (es) | Derivados de pirazolquinolinona, su preparación y su uso terapéutico. | |
| BR112014020826A2 (pt) | moduladores e métodos de uso | |
| BR112015018089A2 (pt) | moduladores de receptor de nmda de espiro-lactama e usos dos mesmos | |
| EA201691368A1 (ru) | ПИРРОЛИДИНИЛСУЛЬФОНОВЫЕ МОДУЛЯТОРЫ RORγ | |
| MX2016002574A (es) | Nuevos moduladores del homologo 6 (sez6) y metodos de uso. | |
| MX2015007213A (es) | Formulaciones de la solución de los anticuerpos anti-il-23p19 manipulados genéticamente. | |
| CY1122731T1 (el) | Διαμορφωτες υποδοχεα οιστρογονων | |
| EA201792258A1 (ru) | ТРИЦИКЛИЧЕСКИЕ СУЛЬФОНЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ RORγ | |
| BR112012032732A2 (pt) | armação de rolo ajustável | |
| CY1123892T1 (el) | Κρυσταλλικες μορφες του 6-((6,7-διμεθοξυκιναζολιν-4-υλο)οξυ)-ν,2-διμεθυλοβενζοφουρανο-3-καρβοξαμιδιου | |
| EA201790046A1 (ru) | Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора | |
| MX2020011826A (es) | Composiciones de combinacion que comprenden compuestos de bisfluoroalquil-1,4-benzodiazepinona y metodos de uso de las mismas. | |
| MX2021002916A (es) | Pirfenidona enriquecida con deuterio y métodos para su uso. | |
| CO2022009691A2 (es) | Formulaciones líquidas de tasimelteón y métodos para su uso |